Aida Pharmaceuticals, Inc. (AIDA)
- Previous Close
0.0000 - Open
0.0002 - Bid --
- Ask --
- Day's Range
0.0002 - 0.0002 - 52 Week Range
0.0002 - 0.0003 - Volume
100 - Avg. Volume
49 - Market Cap (intraday)
8.37M - Beta (5Y Monthly) 21.95
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Aida Pharmaceuticals, Inc., together with its subsidiaries, engages in the formulation, clinical testing, registration, manufacture, sales, and marketing of pharmaceutical and genetic products in mainland China. It offers antibiotics, cardiovascular, and anti-cancer drugs. The company provides its products in the form of powder for injection; and liquid for intravenous injection, capsule, tablet, and ointment. The company provides Etimicin Sulfate, an injectable powder form, as well as rh-Apo2l, a biopharmaceutical therapy for cancers. Aida Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Hangzhou, China.
450
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: AIDA
View MorePerformance Overview: AIDA
Trailing total returns as of 5/23/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AIDA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AIDA
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-5.38%
Return on Assets (ttm)
6.62%
Return on Equity (ttm)
-1.79%
Revenue (ttm)
40.51M
Net Income Avi to Common (ttm)
-2.18M
Diluted EPS (ttm)
-0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
8.28M
Total Debt/Equity (mrq)
237.46%
Levered Free Cash Flow (ttm)
2.27M